

Table 19.8
Non-Hodgkin Lymphoma

5-Year Relative and Period Survival (Percent) by Race, Sex, Diagnosis Year and Age

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
5-Year Relative Survival (Percent)									
Year of Diagnosis:									
1960-1963 ^a	-	-	-	31	31	31	-	-	-
1970-1973 ^a	-	-	-	41	39	43	-	-	-
1975-1977 ^b	46.5	45.6	47.5	46.8	46.3	47.3	48.6	42.6	55.3 ^g
1978-1980 ^b	47.9	46.1	49.8	47.9	46.2	49.5	51.3	47.3	56.7
1981-1983 ^b	50.6	50.3	50.9	50.8	50.5	51.1	49.5	49.2	49.8
1984-1986 ^b	51.6	50.1	53.3	52.0	50.6	53.6	46.8	44.5	49.9
1987-1989 ^b	50.9	47.6	54.9	51.3	48.1	55.2	45.7	41.3	51.0
1990-1992 ^b	50.7	46.7	55.7	51.5	47.6	56.4	42.2	38.2	47.7
1993-1995 ^b	52.5	48.7	57.5	53.2	49.7	57.7	42.1	35.7	54.0
1996-1998 ^b	58.8	57.0	61.0	59.4	57.6	61.5	54.6	53.0	57.0
1999-2001 ^b	63.9	61.4	66.9	64.9	62.8	67.5	55.7	49.0	63.7
2002-2006 ^b	70.3	68.9	71.9	71.6	70.7	72.8	62.4	58.1	67.6
2007-2013 ^b	73.3 ^f	72.5 ^f	74.3 ^f	74.2 ^f	73.5 ^f	75.1 ^f	67.1 ^f	63.5 ^f	71.0 ^f
5-Year Period Survival (Percent)^{cd}									
2013	71.4	69.8	73.3	71.8	70.4	73.5	65.9	61.6	70.8
Stage Distribution (%) 2007-2013^{ce}									
All Stages									
Number of cases	95,444	51,995	43,449	78,911	43,105	35,806	7,881	4,194	3,687
Percent	100%	100%	100%	100%	100%	100%	100%	100%	100%
Localized	28	26	29	27	26	29	28	25	31
Regional	15	15	15	15	15	15	15	14	15
Distant	50	51	48	50	52	49	51	55	47
Unstaged	8	7	8	7	7	8	6	6	7
5-Year Relative Survival (Percent), 2007-2013^c									
Age at Diagnosis:									
Ages <45	82.5	80.1	86.1	84.1	81.7	87.8	71.3	68.2	75.9
Ages 45-54	79.9	76.6	84.8	81.6	78.6	86.1	66.6	61.4	74.1
Ages 55-64	76.3	73.7	79.7	77.4	75.0	80.6	65.1	59.7	71.9
Ages 65-74	70.7	68.3	73.3	71.2	68.8	74.0	64.6	58.6	69.3
Ages 75+	55.0	52.8	56.8	55.4	52.8	57.5	50.2	44.7	52.5
Ages <65	79.0	76.3	82.8	80.3	77.8	83.9	67.9	63.4	74.0
Ages 65+	62.4	60.8	63.9	62.7	60.9	64.5	58.4	53.5	61.5
Stage^e:									
All Stages	71.0	69.5	72.7	71.4	70.0	73.0	65.1	61.3	69.4
Localized	82.9	82.3	83.5	83.0	82.6	83.5	80.0	75.6	83.9
Regional	75.0	74.5	75.4	75.5	75.1	75.9	70.4	69.5	71.0
Distant	63.4	61.9	65.4	64.4	62.8	66.4	55.9	53.0	59.7
Unstaged	69.2	66.6	72.0	67.7	65.0	70.6	61.9	57.6	66.0

^a Based on End Results data from a series of hospital registries and one population-based registry.^b SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).^c Based on follow-up of patients into 2014.^c SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).^d Based on follow-up of patients into 2014.^d Period survival provides a 2013 estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three year calendar blocks (2010-2012: 0-1 year survival),^d (2009-2011: 1-2 year survival), (2008-2010: 2-3 year survival), (2007-2009: 3-4 year survival), (2006-2008: 4-5 years survival).^e Stage at diagnosis is classified using SEER Summary Stage 2000. Stage distribution percentages may not sum to 100 due to rounding.^f The difference between 1975-1977 and 2007-2013 is statistically significant ($p < .05$).^g The standard error is between 5 and 10 percentage points.^h The standard error is greater than 10 percentage points.⁻ Statistic could not be calculated due to fewer than 25 cases during the time period.